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Abstract
Background—HIV testing and counseling (HTC) is essential for successful HIV prevention and 
treatment programs. The national target for HTC is 80% of the adult population in Kenya. 
Population-based data to measure progress towards this HTC target are needed to assess the 
country’s changing needs for HIV prevention and treatment.
Methods—In 2012–2013, we conducted a national HIV survey among Kenyans aged 18 months 
to 64 years. Respondents aged 15–64 years were administered a questionnaire that collected 
information on demographics, HIV testing behavior, and self-reported HIV status. Blood samples 
were collected for HIV testing in a central laboratory. Participants were offered home-based 
testing and counseling to learn their HIV status in the home and point-of-care CD4 testing if they 
tested HIV-positive.
Results—Of 13,720 adults who were interviewed, 71.6% [95% confidence interval (CI): 70.2 to 
73.1] had been tested for HIV. Among those, 56.1% (95% CI: 52.8 to 59.4) had been tested in the 
past year, 69.4% (95% CI: 68.0 to 70.8) had been tested more than once, and 37.2% (95% CI: 35.7 
to 38.8) had been tested with a partner. Fifty-three percent (95% CI: 47.6 to 58.7) of HIV-infected 
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persons were unaware of their infection. Overall 9874 (72.0%) of participants accepted home-
based HIV testing and counseling; 4.1% (95% CI: 3.3 to 4.9) tested HIV-positive, and of those, 
42.5% (95% CI 31.4 to 53.6) were in need of immediate treatment for their HIV infection but not 
receiving it.
Conclusions—HIV testing rates have nearly reached the national target for HTC in Kenya. 
However, knowledge of HIV status among HIV-infected persons remains low. HTC needs to be 
expanded to reach more men and couples, and strategies are needed to increase repeat testing for 
persons at risk for HIV infection.
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INTRODUCTION
HIV continues to be one of the greatest health challenges in the world with an estimated 34 
million people living with HIV infection globally by the end of 2011.1 Sub-Saharan Africa 
carries the heaviest burden of HIV infection, accounting for 69% of the total number of 
people living with HIV and 71% of all new HIV infections.
Improvements in the coverage of antiretroviral therapy (ART) have resulted in broad-based 
health gains in the sub-Saharan Africa region, saving an estimated 9 million life years.1 
Costs to the health care system for sustaining treatment for the number of persons living 
with HIV are high and underscore the importance of reducing transmission and new 
infections if an AIDS-free generation is to be realized.
HIV testing and counseling (HTC) is an essential step towards receiving HIV care and 
treatment among HIV-infected persons and plays an important role in HIV prevention for 
both HIV-infected and uninfected persons. Among people living with HIV, knowledge of 
HIV status has been associated with more than 60% reduction in HIV transmission through 
improved risk-reduction behavior.2 ART itself is now recognized to confer substantial HIV 
prevention benefit, with a demonstrated 96% reduction in transmission within 
serodiscordant couples, further emphasizing the importance of HIV diagnosis.3
In the quest for universal access to HIV testing, a national target for HTC and knowledge of 
HIV serostatus has been set at 80% of the adult population in Kenya.4 Although 
considerable strides have been made toward reaching this target, Kenya faces barriers to 
successful HIV prevention and treatment because of high rates of undiagnosed HIV 
infection. In 2007, only 36% of Kenyans had ever been tested for HIV, citing limited access 
to services and distance to testing sites as major barriers to HIV testing.5 Furthermore, 
among an estimated 1.4 million Kenyans who were HIV infected at that time, 84% were 
unaware of their HIV infection.6
In 2008, Kenya implemented a national HTC strategy to achieve universal testing and 
knowledge of HIV status by 2013.7 The strategy recommended a broader package of HTC 
modalities beyond client-initiated voluntary counseling and testing (VCT) with greater focus 
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on services provided directly to individuals, including provider-initiated testing and 
counseling in health care settings and home-based testing and counseling (HBTC).8,9 
Among 6.8 million HIV tests conducted in 2012, provider-initiated testing and counseling in 
outpatient settings and inpatient wards was the most common testing strategy, representing 
42.7% of all tests conducted; traditional VCT accounted for 38.2% of tests conducted that 
year.10
HBTC, where HTC services are offered to families in the privacy of their home, has been 
successfully implemented in sub-Saharan Africa since the early 2000s.11 Before the 
availability of HBTC in Kenya, 83% of Kenyans in 2007 said they would be willing to 
accept HIV testing in the home should it be offered to them in the future. Since then, HBTC 
has been implemented in high HIV prevalence regions in the country and has resulted in 
high testing rates among those offered the service.12 Self-testing as part of HBTC could 
further increase HTC coverage while addressing the issues of confidentiality for the client13 
but has had limited use to date.
In this article, we assess progress towards achievement of universal access to HTC in Kenya 
using the results from the second Kenya AIDS Indicator Survey (KAIS 2012).
METHODS
Study Setting and Design
KAIS 2012 was a population-based household survey of persons aged 18 months to 64 years 
covering 9 of 10 programmatic regions in Kenya. North Eastern region was not included in 
the survey because of regional insecurity at the time of the study. A 2-stage stratified 
sampling design was used to produce national and regional estimates of HIV indicators. A 
fuller description of the survey methods is described in detail elsewhere.14 This analysis was 
restricted to persons aged 15 to 64 years.
Participants were administered a questionnaire that collected information on demographics, 
sexual behavior, and HIV testing. Questions on HIV testing included whether participants 
had ever been tested for HIV, type of HIV testing received, location and frequency of HIV 
testing, and self-reported HIV status based on the last HIV test conducted.
Central Laboratory Testing
Following the questionnaire, participants provided blood samples for centralized HIV testing 
at the National HIV Reference Laboratory in Nairobi. Specimens were screened for HIV 
antibodies with Vironostika HIV Uni-Form 2012 Plus O Enzyme Immunoassay 
(bioMérieux, Marcy d’Etoile, France) and confirmed using the Murex HIV HIV.1.2.O HIV 
Enzyme Immunoassay (DiaSorin, SpA, Saluggia, Italy). Specimens testing negative on the 
screening assay were classified as HIV-negative, whereas specimens testing positive on the 
screening and confirmatory assays were classified as HIV-positive. Specimens with 
discordant results after confirmatory testing were re-tested using the same testing algorithm. 
Specimens with discrepant results after re-testing were tested with polymerase chain 
reaction (Cobas Amplicor HIV-1 Monitor Test, version 1.5, Roche Molecular Diagnostics, 
Pleasanton, CA) for final HIV results. Central laboratory results were not linked to 
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individuals or households and therefore, the results of these tests were not returned to 
participants.
Home-Based HTC
Survey participants were offered HBTC to learn their HIV status in their home using the 
national HIV testing algorithm for rapid HIV testing.7 After providing informed consent, 
participants were administered pretest counseling by trained HBTC service providers. Rapid 
testing was conducted using a sample of venous blood collected for central laboratory HIV 
testing, unless a venous sample was not provided, in which case a capillary sample was 
collected. An individual was diagnosed as HIV-positive in HBTC after receiving a reactive 
test result on the screening test [Determine HIV-1/2 (Inverness Medical, Waltham, MA)] 
and a subsequent reactive test result on the confirmatory test [Unigold (Trinity Biotech PLC, 
Bray, Ireland)]. Individuals were determined to be HIV-negative after receiving a 
nonreactive result on the screening test. If test results were discrepant between the screening 
and confirmatory test, individuals were referred to a nearby health facility for re-testing. 
Individuals who tested HIV-positive through HBTC were offered point-of-care CD4 testing 
using the PIMA CD4 Analyzer (Alere, Walltham, MA). HBTC service providers delivered 
test results back to participants with post-test counseling and provided referrals for follow-
up services where needed.
Measures
Our two outcomes of interest were ever been tested for HIV and being unaware of HIV 
infection. Persons who had at least 1 HIV test before the survey were defined as persons 
who had ever been tested for HIV. Persons who tested HIV-positive in the central laboratory 
but self-reported that their last HIV test result was HIV-negative, indeterminate, or 
unknown; had not received the test result back; or had never been tested for HIV were 
defined as being unaware of their HIV infection. We examined these outcomes across select 
sociodemographic, behavioral, and clinical variables. These variables included sex, age, 
education, marital status, wealth, residence, region, sexual behavior, history of sexually 
transmitted infection (STI), and pregnancy status for women.
Statistical Analyses
We conducted univariate analysis to describe HIV testing coverage, HIV testing behavior, 
and unawareness of HIV infection by select variables. Bivariate analysis was conducted to 
compare persons who accepted and did not accept HBTC. Data were weighted to account 
for sampling probability, adjusted for survey nonresponse, and presented as weighted 
proportions and 95% confidence intervals. A χ2 test for homogeneity was conducted to test 
for equality of proportions at any specified level of categorical variables. A χ2 test for 
independence was used to test for equality of proportions between populations. P values of 
less than 0.05 were considered statistically significant. Data were analyzed using SAS 
version 9.3 (SAS Institute, Cary, NC).
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Ethical Considerations
The survey protocol was approved by the Ethical Review Committee of the Kenya Medical 
Research Institute, the Committee on Human Research of the University of California, San 
Francisco, and the Institutional Review Board of the US Centers for Disease Control and 
Prevention. Verbal informed consent was obtained from survey participants aged 18 years 
and older and emancipated minors aged 15–17 years (the latter defined as persons below 18 
years who were married, pregnant, or a parent). Consent was provided by parents or 
guardians for minors aged 15–17 years, and assent was provided by the minor participant. 
HBTC was conducted in a private setting around the home, with strict adherence to 
confidentiality. HBTC test results were not shared with any of the survey staff.
RESULTS
Out of 16,383 eligible persons aged 15–64 years, 13,720 (83.7%) agreed to be interviewed. 
Of these, 7954 (58.0%) were women and 5766 (42.0%) were men. Of 13,655 participants 
who provided information on HIV testing history, 71.6% had ever been tested for HIV 
(Table 1). Women were more likely to have ever been tested compared with men (80.4% vs. 
62.5%, P < 0.001).
HIV testing rates were highest among persons aged 25–34 years (84.6%) and lowest among 
persons aged 55–64 years (50.1%) (P < 0.001). Persons who were divorced or separated had 
the highest testing rates (78.9%) followed by persons who were married or cohabiting 
(77.6%) (P < 0.001). Testing rates increased with increasing education level (56.3% for 
those reporting no primary education compared with 74.3% for those reporting secondary 
education or higher, P < 0.001) and wealth index (61.8% for those in the poorest wealth 
category compared with 81.6% among those in the richest wealth category, P < 0.001). 
Urban residents were more likely to have been tested compared with rural residents (79.5% 
vs. 67.0%, P < 0.001). Nairobi region (84.2%) followed by Nyanza region (80.0%) had the 
highest levels of testing, whereas Rift Valley region had the lowest level (66.3%) (P < 
0.001).
Those who perceived themselves to be at great risk for HIV had high testing rates (83.2%) 
compared with those who perceived themselves to be at no risk for HIV (64.1%) (P < 
0.001). Among women, those who had ever been pregnant had higher levels of testing 
(88.9%) compared with those who had never been pregnant (59.7%) (P < 0.001). Nearly all 
(95.1%) women who were currently pregnant had ever been tested for HIV. Among women 
who had given birth in the past 5 years, 93.0% reported that they received an HIV test 
during their last pregnancy (data not shown).15
Among testers, 56.1% reported being tested for HIV in the past year (Table 2). The most 
common testing settings were outpatient clinics (44.0%) followed by VCT settings (30.2%). 
Men were more likely to have been tested at VCT settings (41.3% vs. 22.0%, P < 0.001) but 
equally likely to have tested at outpatient clinics compared with women (43.5% vs. 44.4%). 
In total, 69.4% of participants had been tested for HIV more than once in their lifetime. The 
median number of HIV tests per person was 3 (interquartile range, 2–4) (data not shown).
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The majority of testers had been tested on their own. However, over one-third (37.2%) 
reported that they were tested with a sexual partner in the past. Among those, men were 
more likely to have been tested with a partner (42.0%) compared with women (33.8%) (P < 
0.001). A small proportion (3.5%) of testers reported that they had ever used an HIV self-
test kit, with significantly more men citing use of such kits compared with women (5.2% vs. 
2.3%, P < 0.001). Among all testers, 3.7% self-reported that they were HIV-positive based 
on the results of their last HIV test.
A total of 648 (5.6%) persons were HIV infected based on central laboratory testing. Among 
those, 53.1% were unaware of their HIV infection (Table 3). Unawareness of infection was 
high among men (62.0%), women who had never been pregnant (82.5%), young persons 
aged 15–24 years (82.0%), those reporting no primary education (61.1%), individuals who 
had never been married or cohabited (77.7%) or had been divorced or separated (64.6%), 
those in the richest wealth quintile (65.2%), and persons who did not use a condom with 
their most recent sexual partner in the past 12 months (67.7%). Among HIV-infected 
persons unaware of their infection, 76.4% had been tested for HIV in the past. Of these, 
90.7% reported that they had tested HIV-negative on their last HIV test, and of these, over 
half (55.9%) reported having been tested for HIV in the past year (data not shown).
In total, 9874 (72.0%) of 13,720 survey participants accepted HBTC and received their HIV 
results in the home (Table 4). Compared with persons who accepted HBTC, persons who 
refused were more likely to be in the richest wealth quintile (25.1% vs. 19.0%, P < 0.001), 
live in urban residences (42.0% vs. 35.1%, P = 0.003) and Coast region (11.3% vs. 8.4%, P 
< 0.001), report condom use with the most recent sexual partner in the past 12 months 
(18.8% vs. 15.6%, P = 0.002), have been tested for HIV in the past 3 months (26.1% vs. 
17.7%, P < 0.001), and self-report HIV-positive status (4.6% vs. 1.9%, P = 0.002).
Among those who accepted HBTC, 48.7% were men, one-third (33.8%) were aged 15–24 
years, 29.7% had never been married or cohabited, 52.0% reported secondary education or 
higher, and 64.9% resided in the rural areas. Most (70.7%) had been tested for HIV in the 
past, with 54.4% reporting that their last HIV test was conducted in the past 12 months. 
Over 85% of respondents who accepted HBTC felt they were at no (42.3%) to low (43.1%) 
risk for HIV, while only 4.7% felt they were at great risk for HIV. Among participants who 
accepted HBTC, 1.9% reported a previous HIV-positive diagnosis. The proportion of HIV-
infected persons who were unaware of their HIV infection and accepted HBCT was 68.6% 
(data not shown).
Overall, 4.1% participants tested HIV-positive in HBTC. Of those, 26.6% (n = 78) were on 
ART, and 73.4% (n = 258) were not on ART (data not shown). Among those who accepted 
point-of-care CD4 testing and were not on ART (n = 244), 42.5% had CD4 cell counts ≤350 
cells per micro-liter, and 18.4% had CD4 cell counts ≤200 cells per microliter.
DISCUSSION
In 2012, over 70% of Kenyans aged 15–64 years had ever had an HIV test, double the rate 
observed in 2007 when only 36.6% of adults reported ever having been tested for HIV.6 
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Among women, testing rates increased from 40.7% in 2007 to 80.4% in 2012, achieving the 
universal access target for testing. Among men, a substantial increase in HIV testing was 
also observed from 24.9% in 2007 to 62.5% in 2012, but this still remained below the 
universal access target.
Routine HIV testing for pregnant women attending antenatal clinics (ANC) for prenatal care 
has played a major role in increasing HIV testing rates among women. In 2012, over 90% of 
women who had given birth in the past 5 years received an HIV test at an ANC visit for their 
last pregnancy.15 Still, approximately 5% of women do not attend ANC for prenatal care 
and require alternative approaches for accessing HTC, linkages to ART, and prevention of 
mother-to-child transmission of HIV services.
We found that men who had ever been tested were more likely to have been tested in 
community-based settings (eg, VCT facility and mobile VCT) compared with other venues. 
Community testing programs, therefore, could play an important role in expanding testing to 
underserved men such as those who are less educated and economically disadvantaged. 
Furthermore, innovative testing strategies for men in clinical settings may be needed, 
irrespective of whether they are at the clinic for their own care or accompanying a family 
member, including in antenatal care settings.
Only one-third of testers had ever tested together with a sexual partner. Approximately 4 in 
10 new infections in the country occur within steady heterosexual partnerships,16 and the 
majority of persons in discordant relationships are unaware of their HIV status. Expansion 
of couples-centered HTC can offer major prevention benefit by identifying discordant 
couples and presenting options for reducing risk and transmission within these 
relationships.17,18 The World Health Organization recommends that couple testing be 
expanded in settings where routine HIV testing is offered, with support for mutual 
disclosure to empower couples to make informed decisions about HIV prevention and 
family planning.19 As Kenya begins to implement these recommendations, there will be 
need to assess their feasibility, acceptability, and behavioral and clinical impact among 
couples.
More than half of HIV-infected Kenyans were unaware of their infection, presenting a major 
barrier to HIV prevention and treatment in the country. Over 90% of persons who were 
unaware of their infection had reported that they were HIV-negative based on their last HIV 
test result; over half of these had been tested in the past year. A number of reasons may 
explain the discrepancies between self-reported including recently acquired HIV infection 
since the last HIV test, reluctance in reporting HIV-positive status in a survey setting, false-
negative results on previous HIV tests, or lack of understanding of previous positive test 
results. HIV-infected persons who were unaware of their HIV infection perceived 
themselves to be at no or low risk for HIV infection despite recent testing behavior. The 
national HTC guidelines recommend annual testing for persons with ongoing risk and more 
frequent testing after known occurences of HIV exposure.7 Counseling messages during 
HTC should include comprehensive risk assessment measures and provide recommendations 
on when to re-test for HIV infection.
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Through HBTC, 72.0% of survey participants were tested and received their HIV test results 
within the privacy of their homes. Furthermore, 69% of HIV-infected persons who were 
unaware of their infection learned their HIV status through HBTC. In KAIS 2007 where 
HIV testing was conducted at a central laboratory, test results were made available at a 
nearby health facility approximately 6 weeks after survey teams had visited the households. 
As a result, only 49% of participants who agreed to HIV testing in the survey accessed their 
test results.5 The successful implementation of HBTC in KAIS 2012 demonstrates the 
feasibility of its inclusion in surveys with important benefits to survey participants, 
including immediate knowledge of HIV status, counseling, and early linkage to HIV care.
The proportion of participants who tested HIV-positive in HBTC was 4.1%, lower than the 
prevalence of HIV infection reported in the survey (5.6%).20 Around 28% of survey 
participants did not accept HBTC and of these, 14.2% were HIV-positive based on central 
laboratory HIV testing. These data suggest that some individuals with previously known 
HIV infection declined to participate in HBTC. Although HBTC provides an essential 
service to survey participants, use of HBTC data alone for estimating HIV prevalence in the 
broader population may be subject to bias.
Through point-of-care CD4 testing, we were able to determine that over 40% of HIV-
positive persons identified through HBTC were in need of immediate treatment based on the 
current immunologic criterion for HIV treatment (CD4 ≤ 350 cells per microliter)21; 17% 
had CD4 ≤ 200 cells per microliter, indicative of advanced HIV disease. Sub-Saharan Africa 
is particularly challenged by high rates of late HIV diagnosis of persons in advanced stage of 
HIV disease, late enrollment into HIV care, and delayed initiation of ART leading to poor 
clinical outcomes and higher mortality.22,23 Continued expansion of HTC toward universal 
access, routine re-testing of persons at high-risk for HIV exposure, and point-of-care CD4 
testing at the point of HIV diagnosis can help to increase identification of HIV-infected 
persons and improve early linkages to HIV care for better health outcomes.
This analysis had a few limitations. Our main outcome variables relied on self-report of HIV 
testing behavior and HIV status. It is possible that participants answered according to what 
they perceived to be socially desirable, resulting in a dilution of observed findings. 
Additionally, we relied on historical data around the respondent’s last HIV test, including 
when and where the last HIV test was conducted, allowing for the potential for recall bias. 
Third, because of regional insecurity at the time of the survey, North Eastern region was not 
included in the KAIS 2012 sample, and therefore, results are not generalizable to the country 
as a whole. However, North Eastern region is sparsely populated and the least affected by 
HIV of all regions of Kenya, with an estimated prevalence of HIV infection of less than 
1%.5 It is thus unlikely that exclusion of North Eastern region biased our results 
substantially. Finally, HBTC and point-of-care CD4 testing were provided to participants 
who wanted to learn their HIV status on the day of the survey. As a result, the estimates 
presented on HBTC are specific for a limited sample and not generalizable to the broader 
Kenyan adult population.
Despite these limitations, the results presented in this analysis provide an acceptably 
representative picture of the status of HIV testing in Kenya. KAIS 2012 found high testing 
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rates among adult and adolescent Kenyans, nearly achieving the national testing goal for the 
country. Yet, the majority of HIV infection remains unidentified, contributing to ongoing 
HIV transmission and disease progression in the country. We recommend that the national 
HTC program expands all testing modalities to rapidly identify HIV-infected persons so that 
they can access the care they need immediately. Greater emphasis is required on increasing 
uptake of HTC among couples, promoting retesting among those at high risk for HIV 
infection, and increasing HIV testing in men. The inclusion of HBTC and point-of-care CD4 
testing in this national survey was demonstrated to be feasible, improved knowledge of HIV 
status among participants, and identified a group in need of treatment that would have 
otherwise not sought care. These data will be essential as new strategies for HTC are 
implemented, moving Kenya closer to achieving its universal access targets of prevention, 
care, and treatment.
Acknowledgments
The authors thank the fieldworkers and supervisors for their work during KAIS data collection. They also 
acknowledge all the individuals that participated in this survey. The authors thank Kevin DeCock, George 
Rutherford, Mike Grasso, and Joy Mirjahangir for reviewing and providing input on the article; and the KAIS 
Study Group for their contribution to the design of the survey and collection of the data set: Willis Akhwale, Sehin 
Birhanu, John Bore, Angela Broad, Robert Buluma, Thomas Gachuki, Jennifer Galbraith, Anthony Gichangi, Beth 
Gikonyo, Margaret Gitau, Joshua Gitonga, Mike Grasso, Maya Harper, Andrew Imbwaga, Muthoni Junghae, 
Mutua Kakinyi, Samuel Mwangi Kamiru, Nicholas Owenje Kandege, Lucy Kanyara, Yasuyo Kawamura, Timothy 
Kellogg, George Kichamu, Andrea Kim, Lucy Kimondo, Davies Kimanga, Elija Kinyanjui, Stephen Kipkerich, 
Danson Kimutai Koske, Boniface O. K’Oyugi, Veronica Lee, Serenita Lewis, William Maina, Ernest Makokha, 
Agneta Mbithi, Joy Mirjahangir, Ibrahim Mohamed, Rex Mpazanje, Silas Mulwa, Nicolas Muraguri, Patrick 
Murithi, Lilly Muthoni, James Muttunga, Jane Mwangi, Mary Mwangi, Sophie Mwanyumba, Francis Ndichu, Anne 
Ng’ang’a, James Ng’ang’a, John Gitahi Ng’ang’a, Lucy Ng’ang’a, Carol Ngare, Bernadette Ng’eno, Inviolata 
Njeri, David Njogu, Bernard Obasi, Macdonald Obudho, Edwin Ochieng, Linus Odawo, Jacob Odhiambo, Caleb 
Ogada, Samuel Ogola, David Ojakaa, James Kwach Ojwang, George Okumu, Patricia Oluoch, Tom Oluoch, 
Kenneth Ochieng Omondi, Osborn Otieno, Yakubu Owolabi, Bharat Parekh, George Rutherford, Sandra Schwarcz, 
Shanaaz Sharrif, Victor Ssempijja, Lydia Tabuke, Yuko Takanaka, Mamo Umuro, Brian Eugene Wakhutu, Celia 
Wandera, John Wanyungu, Wanjiru Waruiru, Anthony Waruru, Paul Waweru, Larry Westerman, and Kelly Winter.
Kenya AIDS Indicator Survey (KAIS) 2012 was supported by the National AIDS and STI Control Programme 
(NASCOP), Kenya National Bureau of Statistics (KNBS), National Public Health Laboratory Services (NPHLS), 
National AIDS Control Council (NACC), National Council for Population and Development (NCPD), Kenya 
Medical Research Institute (KEMRI), US Centers for Disease Control and Prevention (CDC/Kenya, CDC/Atlanta), 
United States Agency for International Development (USAID/Kenya), University of California, San Francisco 
(UCSF), Joint United Nations Team on HIV/AIDS, Japan International Cooperation Agency (JICA), Elizabeth 
Glaser Paediatric AIDS Foundation (EGPAF), Liverpool Voluntary Counseling and Testing (LVCT), African 
Medical and Research Foundation (AMREF), World Bank, and Global Fund. This publication was made possible 
by support from the US President’s Emergency Plan for AIDS Relief through cooperative agreements (#PS001805, 
GH000069, and PS001814) from the US Centers for Disease Control and Prevention, Division of Global HIV/
AIDS. This work was also funded in part by support from the Global Fund, World Bank, and the Joint United 
Nations Team for HIV/AIDS.
References
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report. UNAIDS Report on the 
Global AIDS Epidemic 2012. Geneva, Switzerland: UNAIDS; 2012. 
2. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission 
after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 2006; 20:85–92. 
[PubMed: 16327323] 
3. Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral 
therapy. N Engl J Med. 2011; 365:493–505. [PubMed: 21767103] 
Ng’ang’a et al. Page 9
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 March 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
4. Joint United Nations Programme on HIV/AIDS. Getting to Zero: 2011–2015 Strategy. Geneva, 
Switzerland: UNAIDS; 2010. Available at: http://www.unaids.org/en/media/unaids/contentassets/
documents/unaidspublication/2010/jc2034_unaids_strategy_en.pdf.2010
5. National AIDS and STI Control Programme (NASCOP). 2007 Kenya AIDS Indicator Survey Final 
Report. Nairobi, Kenya: NASCOP; 2009. 
6. Cherutich P, Kaiser R, Galbraith J, et al. Lack of knowledge of HIV status a major barrier to HIV 
prevention, care and treatment efforts in Kenya: results from a nationally representative study. PLoS 
One. 2012; 7:e36797. [PubMed: 22574226] 
7. National AIDS and STI Control Programme (NASCOP). National Guidelines for HIV Testing and 
Counseling in Kenya. 2. Nairobi, Kenya: NASCOP; 2010. Available at: http://www.nascop.or.ke
8. World Health Organization (WHO). Guidance on Provider-initiated HIV Testing and Counseling in 
Health Facilities. Geneva, Switzerland: WHO; 2007. Available at: http://www.who.int
9. World Health Organization (WHO). Planning, Implementing and Monitoring Home-based HIV 
Testing and Counseling: A Practical Handbook for xub-Saharan Africa. Geneva, Switzerland: 
WHO; 2012. Available at: http://www.who.int
10. National AIDS and STI Control Programme (NASCOP). National AIDS and STI Control 
Programme, Annual Report. Nairobi, Kenya: NASCOP; 2012. 
11. Sabapathy K, Van den Bergh R, Fidler S, et al. Uptake of home-based voluntary HIV testing in 
sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med. 2012; 9:e1001351. 
[PubMed: 23226107] 
12. Choko AT, Desmond N, Webb EL, et al. The uptake and accuracy of oral kits for HIV self-testing 
in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. PLoS Med. 
2011; 8:e1001102. Epub 2011 Oct 4. 10.1371/journal.pmed.1001102 [PubMed: 21990966] 
13. Dalal W, Feikin DR, Amolloh M, et al. Home-based HIV testing and counseling in rural and urban 
Kenyan communities. J Acquir Immune Defic Syndr. 2013; 62:e47–54. [PubMed: 23075916] 
14. Waruiru W, Kim AA, Kimanga DO, et al. The Kenya AIDS indicator survey 2012: rationale, 
methods, description of participants, and response rates. J Acquir Immune Defic Syndr. 2014; 
66(suppl 1):S3–S12. [PubMed: 24732819] 
15. Sirengo M, Muthoni L, Kellogg TA, et al. Mother-to-child transmission of HIV in Kenya: results 
from a nationally representative survey. J Acquir Immune Defic Syndr. 2014; 66(suppl 1):S66–
S74. [PubMed: 24732822] 
16. Gelmon, L.; Kenya, P.; Oguya, F., et al. Kenya HIV Prevention Response and Modes of 
Transmission Analysis. Nairobi, Kenya: National AIDS Control Council; 2009. 
17. Allen S, Meinzen-Derr J, Kautzman M, et al. Sexual behavior of HIV discordant couples after HIV 
counseling and testing. AIDS. 2003; 17:733–740. [PubMed: 12646797] 
18. Grabbe KL, Bunnell R. Reframing HIV prevention in sub-Saharan Africa using couple-cetered 
approaches. JAMA. 2010; 304:346–347. [PubMed: 20639571] 
19. World Health Organization (WHO). Guidance on Couples HIV Testing and Counseling—
Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples. 
Geneva, Switzerland: WHO; 2012. Available at: http://www.who.int
20. Kimanga DO, Ogola S, Umuro M, et al. Prevalence and incidence of HIV infection, trends, and 
risk factors among persons aged 15–64 years in Kenya: results from a nationally representative 
study. J Acquir Immune Defic Syndr. 2014; 66(suppl 1):S13–S26. [PubMed: 24445338] 
21. National AIDS and STI Control Programme (NASCOP). Guidelines for Antiretroviral Therapy in 
Kenya. 4. Nairobi, Kenya: NASCOP; 2011. Available at: http://www.nascop.or.ke
22. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care 
in the United States and Canada. Clin Infect Dis. 2010; 50:1512–1520. [PubMed: 20415573] 
23. Lahuerta M, Ue F, Hoffman S, et al. The problem of late ART initiation in Sub-Saharan Africa: a 
transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved. 2013; 
24:359–383.10.1353/hpu.2013.0014 [PubMed: 23377739] 
Ng’ang’a et al. Page 10
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 March 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Ng’ang’a et al. Page 11
TABLE 1
HIV Testing Coverage by Select Characteristics of Persons Aged 15–64 Years by Sex, Kenya AIDS Indicator 
Survey 2012
Select Variables Unweighted, n/N Weighted % (95% CI) P*
Total 9947/13,655 71.6 (70.2 to 73.1)
Sex < 0.001
 Women 6329/7907 80.4 (78.9 to 81.9)
 Men 3618/5748 62.5 (60.4 to 64.6)
Age category, yrs < 0.001
 15–24 3009/4515 65.2 (63.0 to 67.5)
 25–34 3288/3831 84.6 (83.1 to 86.2)
 35–44 2028/2562 77.8 (75.9 to 79.7)
 45–54 1075/1689 63.2 (60.4 to 66.1)
 55–64 546/1057 50.1 (45.4 to 54.8)
Marital status < 0.001
 Never married/never cohabited 2360/3967 58.8 (56.4 to 61.2)
 Ever widowed 731/1025 72.0 (67.9 to 76.1)
 Divorced/separated 676/845 78.9 (75.3 to 82.5)
 Married/cohabiting 6175/7812 77.6 (75.9 to 79.2)
Highest educational attainment < 0.001
 No primary 911/1552 56.3 (50.9 to 61.8)
 Primary incomplete 763/1155 64.0 (59.3 to 68.8)
 Primary complete 3173/4299 72.5 (70.6 to 74.3)
 Secondary or higher 5095/6641 74.3 (72.6 to 76.0)
Wealth index < 0.001
 Poorest 1777/2836 61.8 (58.3 to 65.4)
 Second 1961/2842 66.9 (64.2 to 69.5)
 Middle 1961/2661 71.3 (69.2 to 73.5)
 Fourth 1996/2565 76.1 (73.8 to 78.3)
 Richest 2252/2751 81.6 (79.4 to 83.8)
Residence < 0.001
 Rural 5879/8602 67.0 (65.0 to 69.0)
 Urban 4068/5053 79.5 (77.7 to 81.4)
Region < 0.001
 Nairobi 1463/1733 84.2 (81.9 to 86.4)
 Central 1107/1576 69.1 (66.5 to 71.7)
 Coast 1253/1703 72.9 (69.7 to 76.2)
 Eastern 1795/2671 68.2 (64.7 to 71.7)
 Nyanza 1482/1830 80.0 (75.5 to 84.6)
 Rift Valley 1701/2469 66.3 (62.6 to 70.0)
 Western 1146/1673 67.9 (63.8 to 71.9)
Ever pregnant† < 0.001
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Select Variables Unweighted, n/N Weighted % (95% CI) P*
 No 976/1620 59.7 (56.1 to 63.2)
 Yes 5052/5720 88.9 (87.6 to 90.1)
Currently pregnant† < 0.001
 No 5331/6431 83.0 (81.5 to 84.5)
 Yes 408/438 95.1 (92.4 to 97.8)
Lifetime number of partners < 0.001
 0 790/1811 41.8 (38.6 to 45.0)
 1–2 3041/3858 77.7 (75.3 to 80.2)
 2–3 3344/4162 79.1 (77.4 to 80.9)
 4–5 1100/1468 73.8 (71.1 to 76.6)
 6–9 450/596 75.3 (70.7 to 79.8)
 10 or more 589/871 65.6 (61.2 to 70.0)
 Do not know 561/771 73.8 (69.7 to 77.8)
Condom use with most recent sexual partner in past 12 mo‡ 0.004
 No 6299/8017 77.2 (75.6 to 78.8)
 Yes 1247/1495 81.8 (79.3 to 84.3)
Symptoms of sexually transmitted infections in the past 12 mo < 0.001
 No 9353/12,979 70.9 (69.3 to 72.4)
 Yes 594/676 87.3 (84.0 to 90.6)
HIV risk perception < 0.001
 No risk 3344/5050 64.1 (61.9 to 66.3)
 Small risk 3731/4945 74.5 (72.6 to 76.3)
 Moderate risk 968/1190 80.1 (77.3 to 82.9)
 Great risk 428/514 83.2 (79.5 to 86.8)
Participants with missing values were removed from this analysis.
*
P value computed from χ2 test of homogeneity.
†Among women only.
‡Among persons who had sex in the past 12 months.
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TABLE 3
Unawareness of HIV Infection Among HIV-Infected Persons Aged 15–64 Years by Select Characteristics, 
Kenya AIDS Indicator Survey 2012
Unaware of HIV
Select Characteristics Weighted % (95% CI) Unweighted, N Infection Unweighted, n
Total 648 343 53.1 (47.6 to 58.7)
Sex
 Male 193 120 62.0 (53.4 to 70.5)
 Female 455 223 47.8 (42.1 to 53.4)
Age category, yrs
 15–24 75 59 82.0 (72.3 to 91.7)
 25–34 209 121 58.9 (50.5 to 67.4)
 35–44 198 89 42.2 (33.4 to 51.0)
 45–54 126 53 45.1 (34.6 to 55.6)
 55–64* 40 21 48.5 (31.2 to 65.8)
Marital status
 Never married/never cohabited 58 44 77.7 (66.4 to 88.9)
 Ever widowed 165 52 31.5 (24.1 to 39.0)
 Divorced/separated 83 53 64.6 (51.8 to 77.4)
 Married/cohabiting 342 194 56.1 (47.9 to 64.3)
Highest educational attainment
 No primary* 43 26 61.1 (44.1 to 78.2)
 Incomplete primary* 46 23 49.1 (32.9 to 65.4)
 Complete primary 223 123 56.0 (47.2 to 64.7)
 Secondary or higher 335 170 51.2 (44.5 to 57.9)
Wealth index
 Poorest 97 51 49.1 (36.8 to 61.5)
 Second 153 75 49.8 (37.4 to 62.2)
 Middle 137 68 46.8 (36.0 to 57.5)
 Fourth 158 84 55.7 (46.0 to 65.3)
 Richest 102 64 65.2 (54.9 to 75.4)
Residence
 Rural 373 192 51.0 (43.6 to 58.3)
 Urban 275 151 56.0 (47.5 to 64.5)
Region
 Nairobi 67 40 60.0 (47.5 to 72.4)
 Central 60 32 56.3 (41.2 to 71.4)
 Coast 66 40 59.1 (44.2 to 74.0)
 Eastern 75 41 53.6 (37.6 to 69.7)
 Nyanza 242 116 49.7 (40.1 to 59.3)
 Rift Valley 79 47 56.0 (40.1 to 72.0)
 Western 59 27 46.7 (31.2 to 62.2)
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Unaware of HIV
Select Characteristics Weighted % (95% CI) Unweighted, N Infection Unweighted, n
Ever pregnant†
 No* 32 26 82.5 (70.1 to 95.0)
 Yes 400 186 45.7 (39.7 to 51.7)
Currently pregnant†
 No 374 191 49.9 (43.6 to 56.2)
 Yes‡ 21 10 —
Lifetime number of partners
 1 128 71 51.0 (40.3 to 61.6)
 2–3 236 125 54.8 (47.9 to 61.6)
 4–5 105 48 49.1 (37.8 to 60.4)
 6–9* 45 24 53.7 (36.4 to 71.0)
 10 or more 58 29 50.7 (36.7 to 64.8)
 Do not know 62 34 51.2 (36.4 to 66.0)
Condom use with most recent sexual partner in the past 12 mo§
 No 291 202 67.7 (60.3 to 75.1)
 Yes 179 61 37.1 (29.1 to 45.2)
Symptoms of sexually transmitted infections in past 12 mo
 No 574 313 54.4 (48.6 to 60.3)
 Yes 74 30 42.9 (30.0 to 55.9)
Ever been tested for HIV
 No 72 72 100
 Yes 574 269 46.3 (40.5 to 52.1)
When was the last HIV test?
 <3 mo ago 136 56 39.0 (28.9 to 49.2)
 3–5 mo ago 91 48 50.5 (37.5 to 63.5)
 6–11 mo ago 78 44 58.0 (44.1 to 71.9)
 1–2 yrs ago 115 62 53.7 (42.9 to 64.4)
 >2 yrs ago 144 52 36.8 (27.2 to 46.4)
Participants with missing values were removed from this analysis.
*
Denominator between 25 and 49 observations; estimates may be unreliable.
†Among women only.
‡
Due to small denominator (<25 observations), estimates are unreliable and have been suppressed.
§Among persons who had sex in the past 12 months.
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